***Sponsored by Interactive Offers, LLC
NV-387’s Extremely Broad Antiviral is a Host Mimetic That Acts As a Decoy To Attract And Trap Many Diverse Viruses, Preventing the Virus from Replication and Reinfection of Other Cells
ANTIBODIES AND VACCINES ARE OUTDATED: NanoViricides, Inc has a more innovative approach that works even when viruses mutate
In Treating Measles Infection, NV-387 Showed Strong Antiviral Activity, and Significantly, Protected Lungs from Damage, Describes NanoViricides
___________________________
Hello Everyone,
The markets just exploded through all time highs and small caps are starting to catch fire as we finish out the last quarter of 2025 with this new administration that is highly favorable to entrepreneurship.
This next one is a past winner that trades in a tight channel and has a lot of support at its current levels.
NanoViricides, Inc. (NNVC) is pioneering a breakthrough approach to antiviral drug development with its lead candidate NV-387, currently advancing through Phase II clinical trials. This first-in-class compound has demonstrated exceptional efficacy in preclinical models against Influenza, RSV, COVID-19, MPox, and Smallpox—consistently outperforming leading antivirals such as Tamiflu, Remdesivir, and Tecovirimat.
NV-387 introduces a revolutionary “empiric therapy” paradigm that could transform how viral infections are treated. Unlike traditional antivirals, NV-387 allows physicians to begin treatment immediately—without waiting for viral identification. This capability positions NV-387 to capture a multi-billion-dollar global market, estimated at over $20 billion for broad-spectrum respiratory antivirals alone.
In addition, NV-387 is being evaluated for MPox treatment in Africa under preliminary regulatory authorization, with plans to extend these studies to Smallpox under the FDA’s Animal Rule pathway. Success in these areas could establish NNVC as a key global player in pandemic preparedness.
The company is pursuing Orphan Drug Designations and Priority Review Vouchers (PRVs)—which could translate into exclusive market access, accelerated approval timelines, and substantial non-dilutive revenue streams through voucher monetization.
Beyond NV-387, NNVC is advancing NV-HHV-1, targeting Shingles, Chickenpox, and HSV infections, as well as novel anti-HIV therapies that have shown best-in-class efficacy in humanized models.
The company’s proprietary nanoviricide platform mimics the natural virus-binding sites on host cells, enabling it to neutralize viruses before they can infect—a mechanism that bypasses traditional resistance pathways. This platform has the potential to address dozens of viral diseases, from Ebola and Dengue to seasonal influenza, offering broad and scalable commercialization opportunities.
With a fully operational cGMP manufacturing facility, a strong global IP portfolio, and a clear roadmap of value-driving milestones for 2025–2026—including Phase II results, new IND filings, and orphan drug approvals—NanoViricides is poised to deliver transformational growth and long-term shareholder value.
In an era of increasing viral threats, NNVC stands at the forefront of next-generation antiviral innovation—offering investors a rare opportunity to participate in a company with both scientific depth and exponential market potential.
NV-387 – A novel broad-spectrum antiviral
- Since it is a potential cure for RSV infection, and since there is no non-toxic drug for general treatment of RSV infection at present; NV-387 meets an unmet need.
- A therapeutic for treating measles is a completely missing link in the response the the current measles virus outbreak; NV-387 could meet this unmet need too.
- The anti-Influenza activity of NV-387 given orally was substantially superior to all three of the approved anti-influenza drugs (Tamiflu, Rapivab, and Xofluza).
- Bird flu is rampant in poultry in the USA leading to hen culling and soaring egg prices, resulting in a race to find a treatment that works; NV-387 can address it.
- Long COVID also remains a problem for an estimated 17 million adults; an effective antiviral such as NV-387 has already delivered successful Phase 1 results.
- While smallpox is eradicated in the USA, contagious monkeypox has appeared but there is no effective drug treatment for it and competitors clinical trials have failed; NV-387 is entering Phase 2 clinical trials for it.
NanoViricides, Inc. (NYSE American: NNVC)’s lead drug candidate NV-387 (drug product NV-CoV-2), a drug that treats RSV, COVID-19, Long COVID, Influenza, Bird Flu H5N1, and other respiratory viral infections as well as Monkey-pox, has successfully completed Phase 1 clinical trials in healthy subjects with no reported adverse events, even at the highest and repeated dosages. Remarkably, NNVC has been able to develop NV-387 for oral administration already, as well as for injectable and inhalation formulations to enable many modes of use. The Company is currently focused on advancing NV-387 into Phase II human clinical trials for the treatment of RSV infection.
Susceptible viruses CANNOT escape NV-387, even as they continue to evolve in the field into variants. Why? Because no matter how much the virus changes, it continues to use the same host-side signature to bind to and cause infection in the hosts, and thus the nanoviricide would be anticipated to continue to be effective even as the virus mutates to generate variants.
Thus NV-387 and other antiviral drugs designed on the nanoviricides platform can be expected to have decades of effective usability against the target viruses similar to the life of current antibiotics against bacterial infections but in stark contrast to current antiviral approaches.
A broad-spectrum antiviral drug such as NV-387 would be a highly desirable drug globally because it would enable treatment by physicians of patients as soon as they present symptoms of a viral disease without waiting for a test to identify a specific type of viral infection. This is reminiscent of how antibiotics are prescribed, without specific infectious agent identification, relying on the ultra-broad-spectrum of the drug.
NV-387’s Extremely Broad Antiviral is a Host Mimetic That Acts As a Decoy To Attract And Trap Many Diverse Viruses, Preventing the Virus from Replication and Reinfection of Other Cells
Over 90% of human pathogenic viruses are known to use one or more “landing sites” that are in the Sulfated Proteoglycans (“SPG”) family. A successful host-mimetic nanoviricide drug using SPG as the key feature to attract viruses could theoretically be able to attack most if not all such viruses.
NV-387 is designed to mimic SPG and attack the virus as a cell-mimicking decoy. We have accumulated substantial evidence that in lethal viral infection animal studies, NV-387 demonstrated strong antiviral activity against a range of different virus families, exceeding or matching the activity of known approved drug agents.
Superior to Other Treatments?
NV-387 was substantially superior to remdesivir in coronavirus infections, using a model for SARS-CoV-2 (COVID) virus, as reported earlier. We believe that NV-387 continues to be one of the most active antiviral drugs against multiple coronaviruses, and that it is a viable clinical candidate for drug development to treat COVID, Long COVID, as well as potentially MERS, SARS, and seasonal coronavirus infections.
In treating Influenza, NV-387 was substantially superior to the three approved drugs, namely Tamiflu®, Rapivab® , and Xofluza® against an Influenza H3N2 lethal lung viral infection study, as previously reported. We believe that NV-387 is expected to possess strong antiviral activity against H5N1 “Bird Flu” as well, given that H5N1 viruses are known to bind to heparan sulfate proteoglycans, and based on the observed broad-spectrum activity of NV-387.
NNVC has also found that NV-387 is capable of completely curing a lethal RSV lung virus infection in animals, leading to indefinite survival of the animals, as reported recently. There is no cure for RSV, and no approved drug for treatment of RSV infection other than the toxic last-resort drug ribavirin.
Moreover, even novel viruses, whether from natural sources or bio-engineered, are expected to be susceptible to NV-387 if they employ SPG for gaining access to human cells to infect and cause disease. Thus, NV-387 could be highly valuable for preparedness against novel viral epidemics and pandemics.
NV-387 could thus be a single drug to treat all of the “tripledemic” viruses (COVID, RSV, FLU ), and more, when so approved!
Finally, NV-387 was at least as effective as the approved drug tecovitrimat (TPOXX®, SIGA), in a lethal intra-digital infection by ectromelia virus in mice. Importantly, a combined drug made from NV-387 and tecovirimat was more effective than either drug alone, indicating NV-387 “plays well” with tecovirimat and acts by a different mechanism.
- Smallpox poses a significant biodefense threat. Ectromelia virus is a native virus of mice in the poxvirus family and is one of the key animal model viruses for developing smallpox therapeutics. Tecovirimat is an approved drug for treating smallpox infection based on the FDA “Animal Rule”, and is stockpiled by the US “Strategic National Stockpile”. It was mobilized during the recent monkeypox epidemic.
- It is important to develop additional smallpox therapeutics that work well with tecovirimat and by themselves, since viruses pose the threat of drug escape by mutation; further, in a bio-terrorism scenario, a human-engineered smallpox virus resistant to existing drugs could be a potential threat.
In Treating Measles Infection, NV-387 Showed Strong Antiviral Activity, and Significantly, Protected Lungs from Damage, Describes NanoViricides
SHELTON, CONNECTICUT / ACCESS Newswire / October 22, 2025 / NanoViricides, Inc., a publicly traded company (NYSE Amer:NNVC) (the “Company”), announced that its clinical lead drug NV-387 has shown strong activity against the Measles virus in cell culture studies as well as in a humanized animal model. Additionally, NV-387 treatment led to protection of lungs which is very important for keeping severely ill patients alive in late-stage viral infections. Currently, there is no approved drug for treating Measles.
Firstly, NV-387 was found to have direct antiviral effects against Measles virus in standard cell culture-based testing that measured increase in the extent of surviving infected cells upon treatment with the drug (i.e. “CPE” or Cytopathic Effects Assay).
Additionally, in a lethal Measles infection humanized animal model, NV-387 treatment led to a substantial increase in the number of survival days, to 17 days in NV-387-treated animals, from only 7.4 days in untreated animals, an increase of 130%, in a lethal lung infection of humanized mice by Measles virus1, as previously reported.
The increased survival correlated with several improvements in the animal health indicating control of viral infection:
- Slow disease progression, and mild to moderate levels of lung damage as observed in microscopic histopathology.
- Protection of lungs was also evident from the significant reduction in the level of lung plaques (damage to lung tissue) compared to untreated cases.
- Reduction in the level of lung-damaging lymphocytes and neutrophils attracted into the lungs (i.e. infiltration).
These observations indicated that NV-387 treatment led to beneficial effects that protected lungs as well as reduced overall systemic infection.
We have thus found that NV-387 has dual benefits of (i) directly reducing the virus itself, together with (ii) protecting systemic cellular damage, and in particular, protecting lungs from viral damage as well as self-inflicted damage from killer cells.
These benefits make NV-387 an unusual and highly desirable antiviral drug.
NV-387 has completed Phase I clinical trial in healthy subjects with no reportable adverse events, and was found to be safe and well tolerated. In IND-enabling studies, NV-387 was found to be extremely safe and well tolerated in animal models. NV-387 was found to be non-immunogenic, non-allergenic, non-mutagenic, and non-genotoxic.
NV-387 acts by a unique mechanism of action that we call “Re-Infection Inhibition”. NV-387 is designed as a mimic of heparan-sulfate proteoglycan (HSPG) structures that are used by over 90% of human pathogenic viruses as “attachment receptor(s)”, in order to congregate close to cells before being able to bind to the virus’s direct receptors on cells (called the “cognate receptors”) and fusing into the cell. NV-387 “looks like” a cell to the virus, displaying copious amounts of the fragments that mimic HSPG on the nanoviricide micelle surface. This fools the virus into binding to the NV-387, whereupon the shape-shifting NV-387 engulfs the virus, causes lipid-lipid fusion with the virus surface, destroying its ability to infect cells.
NV-387 is available as Oral Gummies, which dissolve slowly in the mouth; and do not require swallowing. Swallowing can be difficult for a patient in presence of a rash.
With Measles outbreaks spreading all across the country, the USA is expected to lose the Measles elimination status, and the virus would be considered endemic thereafter as it was before 2000. Vaccination against Measles is effective, but there are limitations to its public health potential. Measles is extremely contagious, and more than 95% population needs to be vaccinated to eliminate the disease. To complicate the matters, persons with weakened or otherwise affected immune systems do not benefit from vaccination because their immune system cannot mount response to the challenge.
Further, it has become clear in recent years that the Measles virus is drifting from the current vaccine strain (circa 1968) over the last fifty-plus years, and there is some evidence that some variants may have arisen that have greater resistance to the vaccine than in the past.
Thus a drug for combating this emerging infectious disease of Measles is important. As a Company, we note that regulatory development of a drug specific for Measles is not cost-effective, and we will continue to seek non-dilutive grants and contracts support for further development of NV-387 as a treatment for Measles.
NV-387 can be readily developed for Measles through FDA licensure, because it is a multi-purpose, broad-spectrum antiviral. NV-387 is being developed to treat several different viral infections acquired by the respiratory route.
NanoViricides is working on regulatory development of NV-387 as a treatment for viral infections that include RSV, Influenza, Bird Flu H5N1, Coronaviruses, COVID-19, as well as the epidemic-threatening virus causing MPox and the bio-terrorism threat virus of Smallpox.
A Measles Drug with Strong Activity without Toxicity Can Be Available Now for Emergency Use, Says NanoViricides – NV-387 Broad-Spectrum Antiviral with Activity Against Measles Virus
SHELTON, CT / ACCESS Newswire / October 20, 2025 / NanoViricides, Inc., a publicly traded company (NYSE American:NNVC) (the “Company”), announced that its clinical lead drug NV-387 has shown strong activity against the Measles virus in a humanized animal model. The Company announces that NV-387 can now be made available for emergency use application in Measles patients to respond to the spreading Measles outbreaks.
Having a drug to treat patients has become of paramount importance, in view of the fact that the USA is about to return to an endemic playground for the Measles virus, with over 1,600 cases as of October 17, breaking a thirty-year-plus-long record this year1.
“We have already developed an effective drug to respond to the Measles virus outbreaks spreading all across the country,” said Anil R. Diwan, PhD, President.
“NV-387 can be used right away for emergency use in Measles cases,” said Krishna Menon, VMD, MRCS, PhD, Consulting Scientist (Non-Clinical), adding, “With my extensive experience with non-clinical development of several marketed drugs, I can definitely say that NV-387 has excellent activity and safety in treating Measles virus infection.”
Dr. Menon designed and conducted the humanized animal model studies for testing drugs against Measles virus infection. As such, he has hands-on experience with the effects of the drug NV-387. The data has provided compelling evidence that NV-387 is indeed highly effective in protecting the infected from the systemic effects of Measles infection.
“The drug is manufactured under GMP in the USA,” added Jayant Tatake, PhD, Vice President of the Company.
NV-387 has already completed Phase I clinical trial in healthy subjects with no reported adverse events.
The Company has previously reported that in a humanized animal model of lethal Measles infection, NV-387 treatment increased survival of animals to 17 days on average compared to only 7.4 days in untreated animals, an increase of 130%. There were no signs of toxicity from the drug NV-387. Additionally, dose-dependent increase in survival was observed. In contrast, Ribavirin, an unapproved drug that may be used off-label for severe Measles cases as per CDC guidance, is known to be highly toxic.
The Company intends to support any Physician’s Investigator Initiated New Drug Application (IIND) for emergency use of NV-387 for treatment of one or a few cases of Measles, as per FDA regulations. The Company requests physicians that would like to avail of this opportunity to contact us.
NV-387 is a revolutionary novel drug that defines a new mechanism of action, in that it attacks the virus particles and destroys them.
NV-387 is available as Oral Gummies, which dissolve slowly in the mouth; and do not require swallowing. Swallowing can be difficult for a patient in presence of a rash.
With Measles outbreaks spreading all across the country, the USA is expected to lose the Measles elimination status, and the virus would be considered endemic thereafter as it was before 2000. However, Measles is extremely contagious, and more than 95% population needs to be vaccinated to eliminate the disease. To complicate the matters, persons with weakened or otherwise affected immune systems do not benefit from vaccination because their immune system cannot mount response to the challenge.
Further, it has become clear in recent years that the Measles virus is drifting from the current vaccine strain (circa 1968) over the last fifty years, and there is evidence that some variants may have arisen that have greater resistance to the vaccine than in the past.
Thus a drug for combating this emerging infectious disease is important. Regulatory development of a drug specific for Measles is not cost-effective.
NV-387 can be readily developed for Measles through FDA licensure, because it is a multi-purpose, broad-spectrum antiviral. NV-387 is being developed to treat several different viral infections acquired by the respiratory route. The Company is working on regulatory development of NV-387 as a treatment for viral infections that include RSV, Influenza, Bird Flu H5N1, Coronaviruses, COVID-19, the epidemic-threat MPox and the bio-terrorism threat, Smallpox.
NEWS
2 days ago
4 days ago
Oct 15, 2025
NanoViricides, Inc. Has Filed its Annual Report
Sep 30, 2025
Sep 11, 2025
Sep 9, 2025
Aug 18, 2025
Jul 30, 2025
Jul 23, 2025
Jul 21, 2025
Jul 16, 2025
Jul 14, 2025
Jul 1, 2025
Jun 18, 2025
NanoViricides Measles Drug Development Animal Study is Imminent
Jun 4, 2025
MANAGEMENT
Anil R. Diwan, PhD
Executive Chairman, President
Dr. Diwan has been President and Chairman of the Board of the Company since its founding in 2005 Dr. Diwan spearheaded the efforts for the Company’s 2013 uplisting from the OTC Markets to NYSE-American. Dr. Diwan has led several of the Company’s financing efforts since 2010.
Dr. Diwan invented novel polymeric micelle-based nanomedicine technologies as early as 1991. Dr. Diwan is a prolific inventor and a serial entrepreneur. Prior to co-founding NanoViricides, Inc., he has founded TheraCour Pharma, Inc., a privately held company focused in nanomedicines and cell-targeted drug delivery, and AllExcel, Inc., a company with diverse portfolios including nanomedicines, small chemicals, device technologies, as well as informatics. He has won several NIH SBIR (small business innovation research) grant awards. Anil holds a Ph.D. from Rice University, TX, a B.Tech. from Indian Institute of Technology, Mumbai (IIT-B), India, and has consistently held high scholastic ranks and honors. Dr. Diwan has over 25 years of Bio-Pharmaceutical R&D experience with over 20 years as an entrepreneur.
He has several patents issued internationally resulting from three fundamental international patent applications. Under Dr. Diwan’s leadership, NanoViricides, Inc. has been able to keep both administrative and R&D costs at extremely low levels while robustly expanding the drug pipeline every year. Dr. Anil R. Diwan was recognized as “Researcher of the Year” by BusinessNewHaven, a Connecticut Area Business Journal, in 2014.
Ms. Meeta R. Vyas, MBA (Fin.), BS (Chem. Eng.)
interim Chief Financial Officer
Ms. Vyas is known as a strong leader with board level experience and successful achievements as a Senior Executive in a broad range of entities including publicly listed corporations, non-revenue generating entities, and medium to large size companies. Meeta has over twenty-five years of experience in performance and process improvement of both publicly listed companies and non-revenue producing entities, in areas ranging from Finance and Operations to Strategy and Management. Meeta holds the distinction of being the first Indian woman to be named CEO of a publicly listed US corporation, Signature Brands, Inc., best known for “Mr. Coffee” and “Health-O-Meter” brand products. As CEO, acting COO and Vice Chairman of the Board of Signature Brands, Inc., she was responsible for the development and implementation of a turnaround plan, resulting in a return to profitability and growth within a short period of time. Later, as the CEO of the World-Wide Fund for Nature – India (WWF-India) and then as a Vice President of the National Audubon Society (USA), both non-revenue generating entities, Meeta successfully raised unrestricted funding that significantly exceeded annual requirements and also instituted financial processes to measure a variety of performance metrics. Earlier in her career, she was responsible for designing the strategy and initiating the implementation plan for the highly successful information technology outsourcing program at General Electric (GE). Also at GE, Ms. Vyas ran GE Appliances’ Range Products business unit having revenues exceeding $1 Billion where her team doubled operating income in less than two years. Prior to that, as a management consultant with McKinsey and Company, she served publicly listed companies in chemicals, industrial, and technology markets, primarily focusing on growth strategies, valuations, post-merger integrations, and logistics operations. Meeta is married to NanoViricides, Inc. President and Chairman Anil R. Diwan.
Ms. Vyas holds a MBA in Finance from Columbia University’s Graduate School of Business, and a BS in Chemical Engineering from the Massachusetts Institute of Technology.
NanoViricides won the IAIR AWARD as Best North American Company for Leadership in the Nanomedicine Sector.
Randall W. Barton, PhD.
Chief Scientific Officer – Consulting
Dr. Barton has experience in drug discovery and development of both small molecule and biological drug candidates in virology, immunology, inflammation, and cardiovascular diseases in the pharmaceutical and biotech industry as well as academic research and teaching experience. Most recently, he was Vice-President of Drug Discovery at A&G Pharmaceuticals, a biologics and diagnostics company. He retired at the Director level after 20 years at Boehringer Ingelheim Pharmaceuticals. During his time at Boehringer Ingelheim he performed drug development pre-clinical studies on nevirapine (Viramune), a non-nucleoside inhibitor of HIV reverse transcriptase and an important HIV drug.
Prior to joining Boehringer Ingelheim, he was on the faculty at the University of Connecticut Medical School where he was the recipient of an NIH Career Development Award conducting research and teaching in immunology. Dr. Barton has authored over 80 scientific publications, and has been the principal investigator leading to 5 patents. He has a Ph.D. in biochemistry from the University of Tennessee at Oak Ridge National Laboratory and a B.A. from Indiana University.
Jayant Tatake, PhD.
Vice President, R&D
Jay Tatake is an organic chemist with over 25 years of experience in Research and Process Development of fine chemicals. His experience encompasses production scale-up, and large scale manufacture of raw materials for pharmaceuticals. Before joining NanoViricides, Inc., he was Assistant Director of Analytical R&D at Interpharm, Inc. Prior to that, he was Director of Analytical Services at Pharmax Group, Inc. Dr. Tatake has several years experience in Analytical methods development and Quality Control in cGMP environment. His experience includes bio-analytical methods development. Prior to Pharmax Group, he was in the Pharmacology Department, University of Connecticut Health Center, where he synthesized and developed novel bio-conjugates for bio-diagnostics applications.
Jay has a Ph.D. from Department of Chemical Technology, University of Bombay. He is a member of American Chemical Society (ACS). He has published several papers in leading journals and is a co-inventor of several patents.
SINCERELY,
DISCLAIMER
THIS WEBSITE/NEWSLETTER IS OWNED SUBSIDIARY BY DEDICATED INVESTORS, LLC.
OUR REPORTS/RELEASES ARE A COMMERCIAL ADVERTISEMENT AND ARE FOR GENERAL INFORMATION PURPOSES ONLY. WE ARE ENGAGED IN THE BUSINESS OF MARKETING AND ADVERTISING COMPANIES FOR MONETARY COMPENSATION. WE HAVE BEEN COMPENSATED A FEE OF TWENTY THOUSAND USD BY INTERACTIVE OFFERS LLC FOR A ONE DAY NNVC AWARENESS CAMPAIGN. NEVER INVEST IN ANY STOCK FEATURED ON OUR SITE OR EMAILS UNLESS YOU CAN AFFORD TO LOSE YOUR ENTIRE INVESTMENT. THE DISCLAIMER IS TO BE READ AND FULLY UNDERSTOOD BEFORE USING OUR SERVICES, JOINING OUR SITE OR OUR EMAIL/BLOG LIST AS WELL AS ANY SOCIAL NETWORKING PLATFORMS WE MAY USE.PLEASE NOTE WELL: DEDICATED INVESTORS LLC AND ITS EMPLOYEES ARE NOT A REGISTERED INVESTMENT ADVISOR, BROKER DEALER OR A MEMBER OF ANY ASSOCIATION FOR OTHER RESEARCH PROVIDERS IN ANY JURISDICTION WHATSOEVER.RELEASE OF LIABILITY: THROUGH USE OF THIS WEBSITE VIEWING OR USING YOU AGREE TO HOLD DEDICATED INVESTORS LLC, ITS OPERATORS OWNERS AND EMPLOYEES HARMLESS AND TO COMPLETELY RELEASE THEM FROM ANY AND ALL LIABILITY DUE TO ANY AND ALL LOSS (MONETARY OR OTHERWISE), DAMAGE (MONETARY OR OTHERWISE), OR INJURY (MONETARY OR OTHERWISE) THAT YOU MAY INCUR. THE INFORMATION CONTAINED HEREIN IS BASED ON SOURCES WHICH WE BELIEVE TO BE RELIABLE BUT IS NOT GUARANTEED BY US AS BEING ACCURATE AND DOES NOT PURPORT TO BE A COMPLETE STATEMENT OR SUMMARY OF THE AVAILABLE DATA. DEDICATED INVESTORS LLC ENCOURAGES READERS AND INVESTORS TO SUPPLEMENT THE INFORMATION IN THESE REPORTS WITH INDEPENDENT RESEARCH AND OTHER PROFESSIONAL ADVICE. ALL INFORMATION ON FEATURED COMPANIES IS PROVIDED BY THE COMPANIES PROFILED, OR IS AVAILABLE FROM PUBLIC SOURCES AND DEDICATED INVESTORS LLC MAKES NO REPRESENTATIONS, WARRANTIES OR GUARANTEES AS TO THE ACCURACY OR COMPLETENESS OF THE DISCLOSURE BY THE PROFILED COMPANIES. NONE OF THE MATERIALS OR ADVERTISEMENTS HEREIN CONSTITUTE OFFERS OR SOLICITATIONS TO PURCHASE OR SELL SECURITIES OF THE COMPANIES PROFILED HEREIN AND ANY DECISION TO INVEST IN ANY SUCH COMPANY OR OTHER FINANCIAL DECISIONS SHOULD NOT BE MADE BASED UPON THE INFORMATION PROVIDED HEREIN. INSTEAD DEDICATED INVESTORS LLC STRONGLY URGES YOU CONDUCT A COMPLETE AND INDEPENDENT INVESTIGATION OF THE RESPECTIVE COMPANIES AND CONSIDERATION OF ALL PERTINENT RISKS. READERS ARE ADVISED TO REVIEW SEC PERIODIC REPORTS: FORMS 10-Q, 10K, FORM 8-K, INSIDER REPORTS, FORMS 3, 4, 5 SCHEDULE 13D.DEDICATED INVESTORS LLC IS COMPLIANT WITH THE CAN SPAM ACT OF 2003. DEDICATED INVESTORS LLC DOES NOT OFFER SUCH ADVICE OR ANALYSIS, AND DEDICATED INVESTORS LLC FURTHER URGES YOU TO CONSULT YOUR OWN INDEPENDENT TAX, BUSINESS, FINANCIAL AND INVESTMENT ADVISORS. INVESTING IN MICRO-CAP AND GROWTH SECURITIES IS HIGHLY SPECULATIVE AND CARRIES AND EXTREMELY HIGH DEGREE OF RISK. IT IS POSSIBLE THAT AN INVESTORS INVESTMENT MAY BE LOST OR IMPAIRED DUE TO THE SPECULATIVE NATURE OF THE COMPANIES PROFILED.THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995 PROVIDES INVESTORS A SAFE HARBOR IN REGARD TO FORWARD-LOOKING STATEMENTS. ANY STATEMENTS THAT EXPRESS OR INVOLVE DISCUSSIONS WITH RESPECT TO PREDICTIONS, EXPECTATIONS, BELIEFS, PLANS, PROJECTIONS, OBJECTIVES, GOALS, ASSUMPTIONS OR FUTURE EVENTS OR PERFORMANCE ARE NOT STATEMENTS OF HISTORICAL FACT MAY BE FORWARD LOOKING STATEMENTS. FORWARD LOOKING STATEMENTS ARE BASED ON EXPECTATIONS, ESTIMATES, AND PROJECTIONS AT THE TIME THE STATEMENTS ARE MADE THAT INVOLVE A NUMBER OF RISKS AND UNCERTAINTIES WHICH COULD CAUSE ACTUAL RESULTS OR EVENTS TO DIFFER MATERIALLY FROM THOSE PRESENTLY ANTICIPATED. FORWARD LOOKING STATEMENTS IN THIS ACTION MAY BE IDENTIFIED THROUGH USE OF WORDS SUCH AS PROJECTS, FORESEE, EXPECTS, WILL, ANTICIPATES, ESTIMATES, BELIEVES, UNDERSTANDS, OR THAT BY STATEMENTS INDICATING CERTAIN ACTIONS & QUOTE; MAY, COULD, OR MIGHT OCCUR. UNDERSTAND THERE IS NO GUARANTEE PAST PERFORMANCE WILL BE INDICATIVE OF FUTURE RESULTS. IN PREPARING THIS PUBLICATION, DEDICATED INVESTORS LLC HAS RELIED UPON INFORMATION SUPPLIED BY ITS CUSTOMERS, PUBLICLY AVAILABLE INFORMATION AND PRESS RELEASES WHICH IT BELIEVES TO BE RELIABLE; HOWEVER, SUCH RELIABILITY CANNOT BE GUARANTEED. INVESTORS SHOULD NOT RELY ON THE INFORMATION CONTAINED IN THIS WEBSITE. RATHER, INVESTORS SHOULD USE THE INFORMATION CONTAINED IN THIS WEBSITE AS A STARTING POINT FOR DOING ADDITIONAL INDEPENDENT RESEARCH ON THE FEATURED COMPANIES. THE ADVERTISEMENTS IN THIS WEBSITE ARE BELIEVED TO BE RELIABLE, HOWEVER, DEDICATED INVESTORS LLC AND ITS OWNERS, AFFILIATES, SUBSIDIARIES, OFFICERS, DIRECTORS, REPRESENTATIVES AND AGENTS DISCLAIM ANY LIABILITY AS TO THE COMPLETENESS OR ACCURACY OF THE INFORMATION CONTAINED IN ANY ADVERTISEMENT AND FOR ANY OMISSIONS OF MATERIALS FACTS FROM SUCH ADVERTISEMENT. DEDICATED INVESTORS LLC IS NOT RESPONSIBLE FOR ANY CLAIMS MADE BY THE COMPANIES ADVERTISED HEREIN, NOR IS DEDICATED INVESTORS LLC RESPONSIBLE FOR ANY OTHER PROMOTIONAL FIRM, ITS PROGRAM OR ITS STRUCTURE. DEDICATED INVESTORS LLC IS NOT AFFILIATED WITH ANY EXCHANGE, ELECTRONIC QUOTATION SYSTEM, THE SECURITIES EXCHANGE COMMISSION OR FINRA.